As Mike Schuster nears the three-year anniversary of his diagnosis with glioblastoma, he’s already doubled the life expectancy for patients with the deadly cancer.
Technology Ventures News
OMRF has entered a license agreement with Shanghai RAAS Blood Products for development of novel hemophilia treatment.
Lead investor i2E, along with Chicago-based OCA Ventures and Rochester-based Mayo Clinic Ventures, funded in late November the first round of investment to assist Progentec Diagnostics in moving its predictive technology for the onset of lupus flares closer to commercialization.
Progentec Diagnostics, Inc. has completed first round financing of $1.25 million.
This collaboration is part of GSK’s “Discovery Partnerships with Academia” (DPAc) efforts.
QBioMed has the global exclusive rights to develop and market a novel chemotherapeutic drug to treat liver cancer.